Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Shionogi’s antiviral ensitrelvir could shorten COVID-19 symptoms by about a day

By Brian Buntz | March 7, 2023

ShionogiThe investigational antiviral ensitrelvir promises to accelerate recovery from mild to moderate COVID-19.

Investigators concluded that patients who received the investigational drug recovered from COVID-19 symptoms about 24 hours earlier than those in the control group. Additionally, participants in the ensiltrelvir group tested negative for SARS-CoV-2 about 29 hours earlier.

The drug, developed by Shionogi (TYO:4507), also promises to accelerate recovery from long COVID. However, some researchers stress that more data are needed to substantiate that claim.

Dr. Eric Topol, director of the Scripps Research Translational Institute in San Diego, told Nature that it is unclear whether Shionogi defined long COVID before the Phase 2/3 study began. Because Shionogi established the long COVID focus in the study’s exploratory phase, it is impossible to draw firm conclusions, Topol noted.

“As the data gathered on long COVID are exploratory and the results are interim, we were careful not to state any strong conclusions,” noted a Shionogi spokesperson.

 In the study, Shionogi defined long COVID patients as those who consecutively self-reported two or more of the same COVID-19 symptom from previous time of available patient diary. For example, a patient might report symptoms between Day 21 and Day 169. Alternatively, they could report one or more symptoms listed in the pre-defined (Long-COVID) PASC questionnaire on Day 85 or Day 169 (or both).

“As the definition of long COVID continues to be determined, and as it was less clearly defined at the initiation of this study than it is now, it was not possible to prespecify the analysis plan,” the Shionogi spokesperson said. “We do, however, believe many would agree than symptoms occurring three months after the initial infection is a reasonable endpoint.”

Although the data come from a post hoc analysis, “the evidence provides a hypothesis for ensitrelvir’s potential role in reducing the risk of long COVID,” the Shionogi spokesperson noted.

Shionogi notes that the study finding will enable the company to establish predetermined analysis techniques for its ongoing  global Phase 3 clinical trial, SCORPIO-HR (NCT05305547). The multicenter study aims to investigate ensitrelvir’s efficacy in non-hospitalized individuals with symptoms of SARS-CoV-2 infection.

At present, two antivirals, Paxlovid (nirmatrelvir/ritonavir) and molnupiravir, are available to treat COVID-19. Both antivirals, however, are limited to patients at high risk of severe disease. Shionogi investigated ensitrelvir in people regardless of their risk.

Shionogi and Hokkaido University jointly discovered ensitrelvir. The Phase 2/3 study recruited approximately 1,200 participants.

Investigators asked a subset of participants about their COVID-19 symptoms three and six months after trial enrollment. Shionogi concluded that participants had long COVID if they had two or more of the same symptoms at least twice in a row over this period.

Using that standard, they concluded that ensitrelvir recipients had a lower risk of developing long COVID than the placebo group.

Pfizer (Nasdaq:PFE) is currently running a Phase 2/3 study that could inspire the company to study whether Paxlovid is effective against long COVID.

There are, however, multiple, potentially overlapping causes of long COVID, including inflammation, viral reservoirs and autoimmunity. If that proves true, it may be difficult for a single treatment to help all patients with the condition.

Shionogi found that ensitrelvir was well-tolerated in its Phase 2/3 study. In addition, the company reported no serious adverse events or deaths related to treatment. The most common treatment-related adverse events were acute reductions in high-density lipoprotein (HDL) and elevated blood triglyceride levels.

Japanese regulators approved ensitrelvir under an emergency use program in November 2022 under the name Xocova.

Additional regulatory decisions are forthcoming.


Filed Under: Infectious Disease
Tagged With: ensitrelvir
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice 
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.   
FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE